The impact of OCEANIC-AF and the future of factor XIa inhibitors.

The OCEANIC-AF trial was terminated early due to inferiority of asundexian compared with apixaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. ¹ However, the promisingly low bleeding rates support continued exploration of factor XIa inhibitors. Future efforts should focus on achieving greater factor XIa inhibition and identifying patient populations that may benefit most from these therapies.
Competing Interests: Declaration of interests L.P. served as an investigator in the OCEANIC-AF trial and serves as an investigator in the OCEANIC-STROKE trial. G.T. served as a local principal investigator in the OCEANIC-AF trial and serves as a national principal investigator in the OCEANIC-STROKE trial. He also serves on the Steering Committee of the OCEANIC-STROKE trial.
(Copyright © 2024 Elsevier Inc. All rights reserved.)